4Q09 US Copaxone sales of $509M were +33% year-over-year, but they were down 6% vs the $540M booked in 3Q09. Unless the quarter-over-quarter drop was the result of inventory destocking, it could signify that Copaxone demand in the US market has topped out.
Market Data 
Markets 
AI
